Estimation of the Potential Overall Impact of Human Papillomavirus Vaccination on Cervical Cancer Cases and Deaths
This article, published in Vaccine, reports on a study that aimed to estimate the potential real-life impact of the AS04-adjuvanted HPV-16/18 vaccine on cervical cancer cases and deaths at the country level. The authors found that HPV vaccination could prevent a substantial number of cervical cancer cases and deaths in countries worldwide, with associated cost-offsets due to reduced cervical cancer treatment. Cross-protection increased the estimated potential number of cervical cancer cases and deaths prevented by 34 and 18 percent in Africa and Oceania, respectively. Moreover, vaccination could result in a substantial reduction in the number of high-grade precancerous lesions and associated costs.
Author: Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Van Kriekinge G, Castellsagué X, Cibula D, Demarteau N. Estimation of the Potential Overall Impact of Human Papillomavirus Vaccination on Cervical Cancer Cases and Deaths. Vaccine. 2014;32(6):733-739.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)